BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — Europe Revenue Growth YoY by Quarter
BRUKINSA — Europe Revenue Growth YoY (%) (%)
BeOne Medicines BRUKINSA — Europe Revenue Growth YoY: 30.0% in Q2 2026, down 54.9 pts from a year earlier. That is the lowest of the 8 quarters on record here.
Where the Q2 2026 figure comes from
“BRUKINSA sales in the EU totaled $195.6 million in the second quarter, compared to $150.5 million in the prior-year period, representing growth of 30.0%, driven by continued gains in market share across all major markets, including Germany, Italy, Spain, France and the UK.”
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — Europe Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 30.0% | -54.9 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 57.4% | -16.0 pts | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 67.8% | -149.4 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 84.9% | -124.3 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 73.4% | -169.4 pts | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 217.2% | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 209.2% | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 242.8% | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — Europe Revenue Growth YoY (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-eu-yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.